Within the limitations of this systematic review, we can conclude that compared with therapy B, therapy A may provide more benefits for patients with acute exacerbations of COPD. Further large-scale high-quality trials are warranted.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: